AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 261 min read$ATRA

Nguyen AnhCo sold $41K of ATRA

Nguyen AnhCo (President and CEO) sold 5,062 shares of Atara Biotherapeutics, Inc. (ATRA) at $8.08 on 2026-08-17.

Original reporting
SEC EDGAR · Nguyen AnhCo
Published Aug 26, 2026, 11:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 27, 2026, 12:13 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ATRA
Neutral
high confidence
Mentioned
$ATRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATRANeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect Atara's stock price.

02

Market read

Minor insider sell; limited trading relevance.

03

What to watch

Potential upcoming dilution or financing that prompted the sale.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-26

Background

Form 4 filings disclose insider trades; analysts monitor for material changes in insider holdings.

Company-level read

Ticker impact

$ATRANeutralHigh confidence
Context

President and CEO Nguyen AnhCo sold 5,062 shares for $40,883, reducing his stake to 132,775 shares.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to market cap and typical insider activity.

Market effects

Sector

None; isolated insider transaction.

Regional

None; company is US‑listed biotech.

Global

Limited to Atara investors.

Counterpoint

What could challenge this read

Sale could signal insider concern, but size is too small to be material.

Key entities

  • person
    Nguyen AnhCo

    President and CEO of Atara Biotherapeutics.

  • company
    Atara Biotherapeutics, Inc.

    Biotech firm developing gene therapies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATRA insider trading history →

Related articles

AUG 12
$ATRAMed

Atara Biotherapeutics, Inc. (ATRA): Results of Operations and Financial Condition

Atara Biotherapeutics, Inc. (ATRA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress Productive Type A Meeting with FDA for tabelecleucel FDA guidance provided on resubmission of tabelecleucel BLA Year over Year costs and operating expenses reduction of 87%

SEC EDGAR 8-K6 min